Mirabegron 25mg

DRUG6 trials

Sponsors

Buddhist Tzu Chi General Hospital, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh, Far Eastern Memorial Hospital, National Taiwan University Hospital

Conditions

Overactive BladderOveractive Bladder SyndromeRecurrence of Overactive Bladder SyndromeUrinary Bladder, OveractiveUrinary Incontinence

Phase 3

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

CompletedNCT03059134

Buddhist Tzu Chi General HospitalOveractive Bladder Syndrome, Urinary Incontinence

Start: 2015-04-28End: 2016-04-27Updated: 2017-02-23

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

Not yet recruitingNCT07114640

Far Eastern Memorial HospitalUrinary Bladder, Overactive

Start: 2025-08-07End: 2028-12-31Target: 220Updated: 2025-08-11

Phase 4

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

CompletedNCT03558919

Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOveractive Bladder

Start: 2017-01-01End: 2017-12-30Updated: 2018-06-19

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

WithdrawnNCT03695822

Far Eastern Memorial HospitalOveractive Bladder Syndrome

Start: 2018-12-24End: 2019-01-31Updated: 2019-03-07

Unknown Phase

Predictors for Retreatement of OAB After DC Mirabegron

CompletedNCT04550702

National Taiwan University HospitalRecurrence of Overactive Bladder Syndrome

Start: 2015-01-01End: 2019-07-31Updated: 2020-09-16

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Far Eastern Memorial HospitalOveractive Bladder Syndrome

Start: 2021-04-30End: 2024-12-31Target: 500Updated: 2023-03-29